Company Profile
COMPANY
Specialist broker
ISIN
MOLMED
Banca IMI
BLOOMBERG
Via Olgettina 58
20132 Milano
MolMed S.p.A. is a biotechnology company focused on research,
development and clinical validation of novel anticancer therapies.
MolMeds pipeline includes two novel therapeutics in clinical development:
TK, a cell-based therapy enabling bone marrow transplants from partially
compatible donors without post-transplant immune-suppression, in Phase
III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting
agent (VTA), in Phase III in malignant pleural mesothelioma and in Phase
II in six more indications: colorectal, lung (small-cell and non-small-cell),
liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers
top-level expertise in cell and gene therapy to third parties to develop,
conduct and validate projects from preclinical to Phase III trials, including
scale-up and cGMP production of clinical-grade viral vectors, and
manufacturing of patient-specific genetically engineered cells. MolMed is
headquartered at the San Raffaele Biomedical Science Park in Milan, Italy.
The Companys shares are listed on the main market of the Milan Stock
Exchange managed by Borsa Italiana. (Ticker Reuters: MLMD.MI)
C.R.(2)
BOARD MEMBERS
C.C.I.(1)
Independent
Non executive
Executive
CORPORATE GOVERNANCE * (CG)
BOARD MEMBERS
OWNERSHIP
Alfredo Messina
Claudio Bordignon
719,387 shares on 4/11/14
Chairman and CEO
Marina Del Bue
Director
TOP
MANAGEMENT
Alberto Luigi Carletti
Director
Chairman and CEO
Director
Marina Del Bue
Raffaella Ruggiero
General Manager
Director
Germano Carganico
Germano Carganico
General Manager
Director
MLMD.MI
Industry
HEALTH CARE
Auditing company *
Tel.: +3902212771
Fax: +390221277325
www.molmed.com
Deloitte
Super sector
HEALTH CARE
Investor relations *
Market Segment
MTA
Marina Del Bue
E-mail:investor.relations@molmed.com
Tel.:+39 02.21277.371 - Fax:+39 02.21277.325
KEY FIGURES *
€m
First-Half Results
30/06/13
30/06/12
2.49
2.20
Total Sales
Ebitda
Ebitda margin
Ebit
Ebit Margin
Ebt
Ebt margin
Net Result
E-Margin
-10.05
-403.98%
-10.20
-409.85%
-10.20
-409.85%
Net Financial Debt / (Cash)
Net Equity
Capital Employed
First-Half Results
30/06/13
30/06/12
-12.70
-28.91
18.02
34.17
5.32
5.26
Claudio Bordignon
Maurizio Carfagna
MLM IM
REUTERS
Mario Masciocchi
Lead Independent Director
IT0001080248
Var %
'13 vs '12
13.09%
Annual Results
31/12/12
31/12/11
5.06
2.70
-11.05
-502.36%
-10.71
-486.96%
-10.71
-486.96%
-22.38
-442.42%
-22.00
-434.89%
-22.00
-434.89%
Var %
'13 vs '12
-22.68
-840.00%
-21.57
-798.85%
-21.57
-798.85%
Annual Results
31/12/12
31/12/11
-17.53
-38.67
23.29
44.82
5.76
6.15
-47.26%
1.06%
Source: company data. The year-end closing is at December, 31. Values are expressed in Million Euro.
Sabina Grossi
OTHER
INFORMATION
RELATING
GOVERNANCE
Director
Alfredo Messina
Director
Lorenzo Salieri
SHARE ANALYSIS
Number of shares outstanding
Ordinary
Nominal value (€)
Director
List based voting
system (BoD / MB)
Gianluigi Fiorendi
Director
Riccardo Cortese
Quorum for minority
shareholders
Director
4.5%
Record Date
Quantity
234,139,264
234,139,264
Last Divid. (€)
n/a
Ordinary
Capitalis. (€ m)
113.09
113.09
--.-Detach Date
n/a
(1): Internal Control Committee (2): Compensation Committee (3): Nomination
Committee
(CG) Corporate Governance: Traditional Model
SHAREHOLDERS *
H-INVEST SPA: 3.57%
H-EQUITY SRL: 4.01%
SCIENCE PARK RAF SPA IN
LIQUIDAZIONE: 5.11%
AIRAIN LDA: 5.70%
FININVEST SPA: 25.30%
Last price
Ord
Performance
Ord
28/01/2015
0.48
-2Y
11.13%
-2Y
INDEX ITSC
17.52%
Relative perf.
-6.39%
Price range (-2y)
Ord
-1Y
-39.55%
-1Y
-1.20%
-38.35%
MAX
0.85
-3M
2.31%
-3M
7.21%
-4.90%
MIN
0.40
-1M
7.31%
-1M
8.32%
-1.01%
ALTRI < 2%: 53.18%
TURNOVER AND VOLATILITY - STATISTICS FROM 02/01/2015 TO28/01/2015
Source: MolMed Update: 02/10/2014
Turn over
Total(€)
Daily average(€)
8,377,883
440,941
Number of shares traded
Total
Daily average
18,242,761
960,145
Number of trades
Total
Daily average
4,778
251
A
Volatility
33.29%
A
Turnover velocity
104.16%
Source: Borsa Italiana. Data refer to the ordinary shares.
OTHER LISTED INTRUMENTS ON BIT MARKET
IDEM STOCK FUTURES
SECURITISED DERIVATIVES
WARRANTS
STOCK OPTIONS
LISTED BONDS
ANALYST REPORTS
Analyst reports from www.borsaitaliana.it: Banca Intermediazione Mobiliare - IMI (14/11/2014) Banca Intermediazione Mobiliare - IMI
(17/09/2014) Banca Intermediazione Mobiliare - IMI (11/03/2014)
* The above information has been provided and updated by the issuing company